{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:17:03Z","timestamp":1783127823444,"version":"3.54.6"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2314-B-010-042"],"award-info":[{"award-number":["109-2314-B-010-042"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-A49-038-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-A49-038-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113C-088"],"award-info":[{"award-number":["V113C-088"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112EP-002"],"award-info":[{"award-number":["V112EP-002"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112E-008-3"],"award-info":[{"award-number":["V112E-008-3"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112C-066"],"award-info":[{"award-number":["V112C-066"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113EP-005"],"award-info":[{"award-number":["V113EP-005"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.tjog.2025.11.028","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:47:32Z","timestamp":1782485252000},"page":"744-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression varies significantly across ovarian cancer histotypes"],"prefix":"10.1016","volume":"65","author":[{"given":"Shih-Yao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Ming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hou","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Ru","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2025.11.028_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.tjog.2025.11.028_bib2","doi-asserted-by":"crossref","first-page":"m3773","DOI":"10.1136\/bmj.m3773","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.tjog.2025.11.028_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.tjog.2025.11.028_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.tjog.2025.11.028_bib5","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.tjog.2025.11.028_bib6","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2147\/OTT.S162447","article-title":"Targeting Trop-2 in solid tumors: future prospects","volume":"12","author":"Zaman","year":"2019","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.tjog.2025.11.028_bib7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tjog.2024.09.006","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (II): anti-HER2\/neu","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.028_bib8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1349-7006.2002.tb01231.x","article-title":"HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab","volume":"93","author":"Fujimura","year":"2002","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.tjog.2025.11.028_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2003.09.030","article-title":"In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer","volume":"92","author":"Cloven","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/15384047.2017.1310343","article-title":"Relationship between HER2 and JAK\/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer","volume":"18","author":"Shang","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.tjog.2025.11.028_bib11","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1038\/s41598-024-57515-y","article-title":"Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjog.2025.11.028_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib13","series-title":"FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors","year":"2024"},{"key":"10.1016\/j.tjog.2025.11.028_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1309\/AJCPGXK0FR4MHIHB","article-title":"Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker","volume":"134","author":"Derycke","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.tjog.2025.11.028_bib15","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejca.2009.12.019","article-title":"Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients","volume":"46","author":"Bignotti","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tjog.2025.11.028_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/iep.12174","article-title":"Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma","volume":"97","author":"Xu","year":"2016","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.tjog.2025.11.028_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ygyno.2011.03.002","article-title":"High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody","volume":"122","author":"Varughese","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer","volume":"10","author":"Perrone","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib19","article-title":"Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer","volume":"54","author":"Greenman","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.tjog.2025.11.028_bib20","series-title":"Female genital tumours","year":"2020"},{"key":"10.1016\/j.tjog.2025.11.028_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tjog.2025.11.028_bib22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/jclinpath-2011-200082","article-title":"Dual-colour HER2\/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours","volume":"64","author":"Yan","year":"2011","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.tjog.2025.11.028_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/his.14419","article-title":"Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma","volume":"79","author":"Lin","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.tjog.2025.11.028_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/PGP.0000000000000812","article-title":"HER2 protein overexpression and gene amplification in tubo-ovarian high-grade serous carcinomas","volume":"41","author":"Ersoy","year":"2022","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.tjog.2025.11.028_bib25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.tjog.2025.11.028_bib27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2025.11.028_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2025.11.028_bib29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2025.11.028_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target","volume":"59","author":"Stepan","year":"2011","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.tjog.2025.11.028_bib32","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with Nectin-4-Positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib33","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib34","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2025.11.028_bib35","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2025.11.028_bib36","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.tjog.2025.11.028_bib37","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib38","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2025.11.028_bib39","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-Positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926001609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455926001609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:32:16Z","timestamp":1783125136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455926001609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1028455926001609"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2025.11.028","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression varies significantly across ovarian cancer histotypes","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2025.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}